Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yueqiang Jiang

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Medicine|October 14, 2018
A 5-year follow-up of primary seminal vesicle adenocarcinoma: A case reportTiejun Yin, Yueqiang Jiang
Gland Surgery|August 11, 2020
Ectopic thyroid as multiple nodules in bilateral lung lobes: a case reportLing Cheng, Xudong Jiang, Yueqiang Jiang
Oncotargets and Therapy|March 11, 2017
Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trialsLifen Qiao, Jin Wang, Guoxian Long, et al.
Oncotarget|September 1, 2018
Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activityYueqiang Jiang, Yanling Ma, RuiChao Li, et al.
Oncotarget|March 20, 2018
Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activityYueqiang Jiang, Yanling Ma, RuiChao Li, et al.
Clinical Breast Cancer|September 9, 2019
TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast CancerYueqiang Jiang, Yan Liu, Xiaolong Tan, et al.
Journal of Thoracic Disease|February 27, 2024
Prognosis of immunotherapy for non-small cell lung cancer with <i>CDKN2A</i> loss of functionLu Zhao, Xiao Zhou, Hui Li, et al.
Frontiers in Oncology|May 13, 2024
A case report of sustained remission after radiotherapy combined with ICI in NEPC with primary drug resistance to chemotherapyTengfei Li, Yanan Wang, Yueqiang Jiang, et al.
Journal of Translational Medicine|February 3, 2024
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospectsSiyuan Wang, Jiaxin Wang, Yu Xia, et al.
Annals of Palliative Medicine|February 7, 2021
Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case reportYueqiang Jiang, Jun Zhang, Xudong Jiang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Medicine|October 14, 2018
A 5-year follow-up of primary seminal vesicle adenocarcinoma: A case reportTiejun Yin, Yueqiang Jiang
Gland Surgery|August 11, 2020
Ectopic thyroid as multiple nodules in bilateral lung lobes: a case reportLing Cheng, Xudong Jiang, Yueqiang Jiang
Oncotargets and Therapy|March 11, 2017
Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trialsLifen Qiao, Jin Wang, Guoxian Long, et al.
Oncotarget|September 1, 2018
Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activityYueqiang Jiang, Yanling Ma, RuiChao Li, et al.
Oncotarget|March 20, 2018
Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activityYueqiang Jiang, Yanling Ma, RuiChao Li, et al.
Clinical Breast Cancer|September 9, 2019
TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast CancerYueqiang Jiang, Yan Liu, Xiaolong Tan, et al.
Journal of Thoracic Disease|February 27, 2024
Prognosis of immunotherapy for non-small cell lung cancer with <i>CDKN2A</i> loss of functionLu Zhao, Xiao Zhou, Hui Li, et al.
Frontiers in Oncology|May 13, 2024
A case report of sustained remission after radiotherapy combined with ICI in NEPC with primary drug resistance to chemotherapyTengfei Li, Yanan Wang, Yueqiang Jiang, et al.
Journal of Translational Medicine|February 3, 2024
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospectsSiyuan Wang, Jiaxin Wang, Yu Xia, et al.
Annals of Palliative Medicine|February 7, 2021
Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case reportYueqiang Jiang, Jun Zhang, Xudong Jiang, et al.
Pageof 2